Seagen to highlight research in urothelial cancer at the 2023 american society of clinical oncology genitourinary cancers symposium

Bothell, wash.--(business wire)--seagen inc. (nasdaq: sgen) today announced the presentation of new data featuring padcev® (enfortumab vedotin-ejfv) at the upcoming american society of clinical oncology genitourinary cancers symposium (asco-gu) taking place from february 16-18, 2023. a podium presentation will feature noteworthy patient-reported outcomes from the registrational phase 1b/2 ev‐103 cohort k study.
SGEN Ratings Summary
SGEN Quant Ranking